524 related articles for article (PubMed ID: 31421115)
1. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
2. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
4. Acanthoic acid, a diterpene in Acanthopanax koreanum, ameliorates the development of liver fibrosis via LXRs signals.
Bai T; Yao YL; Jin XJ; Lian LH; Li Q; Yang N; Jin Q; Wu YL; Nan JX
Chem Biol Interact; 2014 Jul; 218():63-70. PubMed ID: 24802811
[TBL] [Abstract][Full Text] [Related]
5. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
6. Acanthoic acid protectsagainst ethanol-induced liver injury: Possible role of AMPK activation and IRAK4 inhibition.
Yao YL; Han X; Song J; Zhang J; Li YM; Lian LH; Wu YL; Nan JX
Toxicol Lett; 2017 Nov; 281():127-138. PubMed ID: 28964808
[TBL] [Abstract][Full Text] [Related]
7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
8. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
9. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
Yan C; Zhang Y; Zhang X; Aa J; Wang G; Xie Y
Biomed Pharmacother; 2018 Sep; 105():274-281. PubMed ID: 29860219
[TBL] [Abstract][Full Text] [Related]
10. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
12. Acanthoic Acid Can Partially Prevent Alcohol Exposure-Induced Liver Lipid Deposition and Inflammation.
Yao YL; Han X; Li ZM; Lian LH; Nan JX; Wu YL
Front Pharmacol; 2017; 8():134. PubMed ID: 28360860
[No Abstract] [Full Text] [Related]
13. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
[TBL] [Abstract][Full Text] [Related]
14. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
15. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Hepatic Lipogenesis by Loliolide and Pinoresinol from
Kim SY; Lee JY; Jhin C; Shin JM; Kim M; Ahn HR; Yoo G; Son YJ; Jung SH; Nho CW
J Agric Food Chem; 2019 Nov; 67(45):12419-12427. PubMed ID: 31610126
[TBL] [Abstract][Full Text] [Related]
17. Lycopene Prevents DEHP-Induced Liver Lipid Metabolism Disorder by Inhibiting the HIF-1α-Induced PPARα/PPARγ/FXR/LXR System.
Zhao Y; Ma DX; Wang HG; Li MZ; Talukder M; Wang HR; Li JL
J Agric Food Chem; 2020 Oct; 68(41):11468-11479. PubMed ID: 32962341
[TBL] [Abstract][Full Text] [Related]
18. Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis.
Lin YN; Wang CCN; Chang HY; Chu FY; Hsu YA; Cheng WK; Ma WC; Chen CJ; Wan L; Lim YP
J Agric Food Chem; 2018 Nov; 66(44):11647-11662. PubMed ID: 30359008
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
